解析估计目标框架:以肿瘤患者报告结局为例
患者报告结局(PRO)在肿瘤药物获益-风险评估中日益重要,但其研究目标常定义不清。本文基于ICH E9(R1)附录,面向多利益相关方概述估计目标框架,并以乳腺癌假想试验中的躯体功能为例,演示如何用该框架制定具体的PRO研究目标,以改善设计、分析与解读。
要点
- PRO研究目标常定义不清,可导致对患者体验的误导性结论。
- 估计目标框架通过多学科方法对齐试验目标、设计与分析。
- 以乳腺癌假想试验的躯体功能为例,演示如何制定具体PRO研究目标。
核心结论
- 使用估计目标框架审评肿瘤医疗产品并标注PRO,可改善利益相关方沟通并更清晰解读患者体验。
研究设计与样本
- 本文为政策综述,基于ICH E9(R1)附录提供估计目标框架概述,面向多利益相关方。
- 以乳腺癌假想试验中的躯体功能为例,应用估计目标框架制定具体PRO研究目标。
临床怎么用
- 在肿瘤临床试验中应用估计目标框架制定PRO研究目标,以改善设计、分析与解读。
- 该框架采用多学科方法,可用于审评医疗产品并标注PRO。
局限性
- 本文不 endorsement 特定研究设计或结局,仅展示估计目标框架原则在研究设计中的应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patient-reported outcome (PRO) measures describe how a patient feels or functions and are increasingly being used in benefit-risk assessments in the development of cancer drugs. However, PRO research objectives are often ill-defined in clinical cancer trials, which can lead to misleading conclusions about patient experiences. The estimand framework is a structured approach to aligning a clinical trial objective with the study design, including endpoints and analysis. The estimand framework uses a multidisciplinary approach and can improve design, analysis, and interpretation of PRO results. On the basis of the International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use E9(R1) addendum, we provide an overview of the estimand framework intended for a multistakeholder audience. We apply the estimand framework to a hypothetical trial for breast cancer, using physical function to develop specific PRO research objectives. This Policy Review is not an endorsement of a specific study design or outcome; rather, it is meant to show the application of principles of the estimand framework to research study design and add to ongoing discussion. Use of the estimand framework to review medical products and label PROs in oncology can improve communication between stakeholders and ultimately provide a clearer interpretation of patient experience in the development of oncological drugs.
引用
- Fiero MH, Pe M, Weinstock C, et al. Demystifying the estimand framework: a case study using patient-reported outcomes in oncology. Lancet Oncol. 2020. PMID: 33002444. doi:10.1016/S1470-2045(20)30319-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。